ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.

• Status: Approved for marketing
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study is to evaluate the effects (good and bad) of ALIMTA and Cisplatin or ALIMTA alone on you and your malignant pleural mesothelioma as well as make ALIMTA available to patients who qualify for treatment.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Cisplatin; Pemetrexed

Criteria

Inclusion Criteria:

• Have a proven diagnosis of malignant mesothelioma in patients not candidates for curative surgery

• Prior chemotherapy for your disease is allowed

• Measurable lesion is not required

• Have a adequate performance status

• Sign an informed consent form

Exclusion Criteria:

• You are excluded from this trial if you have received any investigational agent within 4 week before enrolling in this study

• You are excluded from this trial if you have received radiation within the previous 2 weeks

• You are excluded from this trial if you are a candidates for curative surgery